OPEN Health and Pharmerit Combine the Best of Both Worlds

Discover where the next step in your career could take you.

VIEW OPEN POSITIONS
Pharmerit OPEN Health Circle

Why Pharmerit and OPEN Health?

Together, we offer a truly comprehensive suite of services to identify and address evidence gaps and deliver world class communications across a wide range of media. Combined with our broad scope of therapeutic expertise, we produce results and solutions that are of the highest quality.

About Us
View Publications

What We Do

Our multidisciplinary teams work across 4 Centers of Excellence to communicate a product’s value.

Modeling and Meta-Analysis

Modeling and Meta-Analysis

Developing tools to inform policy decision makers about the clinical and health economic consequences of health technologies

Learn more
Real-World Evidence and Data Analytics

Real-World Evidence and Data Analytics

Designing studies using data from patient medical records, insurance claims, and clinical trials.

Learn more
Patient-Centered Outcomes

Patient-Centered Outcomes

Developing, refining, and analyzing outcomes, quantifying values, and optimizing study designs to highlight the patient voice.

Learn more
Strategic Market Access

Strategic Market Access

Communicating evidence regarding unmet needs and the benefits and costs of treatment innovations to ensure market access.

Learn more

Our Combined Experience

We work with 90% of the top pharma brands across a wide range of therapeutic areas.

1,200+

Publications

20+

Years of Innovation

700+

Dedicated Employees

200+

Sponsors

Latest News and Views

View News

Solving pharma’s biggest challenges

People are at the heart of our business. Without our incredibly talented people, we couldn’t offer our clients the world-class service they have come to expect.

We know how important it is to support, develop, reward and encourage our team. And that’s just part of what makes Pharmerit – an OPEN Health Company a great place to work.

View Open Positions
Meet The Experts

Latest News

View News
  • chemotherapy

What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma

January 18th, 2021|Comments Off on What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma

What Did Time Tell Us? A Comparison and

Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis

January 13th, 2021|Comments Off on Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis

Direct Medical Costs Associated With Treatment Nonpersistence in

Partner with Pharmerit and OPEN Health

    Looking for innovation? Contact us today.

    Pharmerit and OPEN Health